Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

ClinicalTrials.gov ID: NCT00419393

Public ClinicalTrials.gov record NCT00419393. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.

Study identification

NCT ID
NCT00419393
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
190 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2007 (Type not available)
Primary completion
Mar 2010 (Actual)
Completion
Mar 2010 (Actual)
Last update posted
Sep 5, 2014

2007 – 2010

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
Not listed Dothan Alabama — —
Not listed Northport Alabama — —
Not listed Phoenix Arizona — —
Not listed Little Rock Arkansas — —
Not listed Bakersfield California — —
Not listed Loxahatchee Groves Florida — —
Not listed Atlanta Georgia — —
Not listed Suwanee Georgia — —
Not listed Witchita Kansas — —
Not listed Detroit Michigan — —
Not listed Camden New Jersey — —
Not listed Buffalo New York — —
Not listed Cedarhurst New York — —
Not listed Toledo Ohio — —
Not listed Tulsa Oklahoma — —
Not listed San Antonio Texas — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00419393, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 5, 2014 · Synced Nov 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00419393 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →